Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Production of an Antibody Fragment (Scfv) Targeting Pcrv Protein of Pseudomonas Aeruginosa in Fed-Batch Cultivation Mode Publisher Pubmed



Karam S1, 2 ; Raigani M2 ; Afshar SH1, 2 ; Talebkhan Y2 ; Bayat E2 ; Komijani S2 ; Nematollahi L2 ; Barkhordari F2 ; Ardestani MS3 ; Davami F2
Authors

Source: Iranian Biomedical Journal Published:2021


Abstract

Background: Pseudomonas aeruginosa is one of the opportunistic pathogens causing frequent hospital-acquired life-threatening infections in mechanically ventilated patients. The most significant virulence factor of P. aeruginosa is T3SS. PcrV is an important structural protein of the T3SS. Methods: In the current investigation, a recombinant scFv mAb against the PcrV protein was expressed in EnBase® (fed-batch) cultivation mode. The pETiteTM N-His SUMO Kan vector, including anti-PcrV scFv gene, was transformed into Escherichia coli (BL21) cells. The expression and solubility of anti-PcrV scFv protein were investigated at two different temperatures (25 °C and 30 °C) and at different induction times (4, 6, 8, 12, and 24 hours). Results: Increased efficiency was achieved by EnBase® compared to LB broth; owing to the slow release of glucose, the maximum level of solubility and total protein expression was observed in EnBase® cultivation system at 30 °C and 24 h post induction. Furthermore, IC50 for anti-PcrV scFv protein was determined to be approximately 7 μg/mL. Conclusion: Anti-PcrV scFv produced in this study showed promising in vitro results, protecting RBC from lysis by P. aeruginosa (exoU+). © 2021, Pasteur Institute of Iran. All rights reserved.
Other Related Docs
9. The Use of Nanoparticles As a Promising Therapeutic Approach in Cancer Immunotherapy, Artificial Cells# Nanomedicine and Biotechnology (2016)
10. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)